학술논문
Golidocitinib, a selective JAK1 tyrosine-kinase inhibitor, in patients with refractory or relapsed peripheral T-cell lymphoma (JACKPOT8 Part B): a single-arm, multinational, phase 2 study
Document Type
Article
Author
Song, Yuqin; Malpica, Luis; Cai, Qingqing; Zhao, Weili; Zhou, Keshu; Wu, Jianqiu; Zhang, Huilai; Mehta-Shah, Neha; Ding, Kaiyang; Liu, Yao; Li, Zengjun; Zhang, Liling; Zheng, Meifang; Jin, Jie; Yang, Haiyan; Shuang, Yuerong; Yoon, Dok Hyun; Gao, Sujun; Li, Wenyu; Zhai, Zhimin; Zou, Liqun; Xi, Yaming; Koh, Youngil; Li, Fei; Prince, Miles; Zhou, Hui; Lin, Lie; Liu, Hui; Allen, Pamela; Roncolato, Fernando; Yang, Zhenfan; Kim, Won-Seog; Zhu, Jun
Source
In The Lancet Oncology January 2024 25(1):117-125
Subject
Language
ISSN
1470-2045